Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC02T)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224672

Enrollment

500

Registered

2019-05-09

Start date

2019-05-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

investigational material(s) Generic name etc : Fycompa INN of investigational material : Perampanel Therapeutic category code : 113 Antiepileptics Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Epilepsy participants from 12 to 17 years of age with: 1) Partial seizures (with or without secondary generalized seizures) 2) Primary generalized Tonic-clonic seizures

Exclusion criteria

Exclusion criteria: Participants previously treated with Fycompa

Design outcomes

Primary

Measure	Time frame
safety 1. Number of participants with any serious adverse event 2. Number of participants with any non-serious adverse event	—

Secondary

Measure	Time frame
efficacy 1.Seizure frequency 2.Overall improvement rating	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026